Octreotide-targeted liposomes loaded with CPT-11 enhanced cytotoxicity for the treatment of medullary thyroid carcinoma.
暂无分享,去创建一个
[1] Y. Maitani,et al. Combination of RET siRNA and irinotecan inhibited the growth of medullary thyroid carcinoma TT cells and xenografts via apoptosis , 2010, Cancer science.
[2] A. Grossman,et al. Medullary Thyroid Cancer: Molecular Biology and Novel Molecular Therapies , 2009, Neuroendocrinology.
[3] Li Shi,et al. Novel irinotecan-loaded liposome using phytic acid with high therapeutic efficacy for colon tumors. , 2009, Journal of controlled release : official journal of the Controlled Release Society.
[4] T. Honda,et al. Design of Folate-Linked Liposomal Doxorubicin to its Antitumor Effect in Mice , 2008, Clinical Cancer Research.
[5] Yu-Chih Liang,et al. Liposome encapsulation reduces cantharidin toxicity. , 2008, Food and chemical toxicology : an international journal published for the British Industrial Biological Research Association.
[6] M. Korbonits,et al. Somatostatin analogues in the control of neuroendocrine tumours: efficacy and mechanisms. , 2008, Endocrine-related cancer.
[7] Shih-Kwang Wu,et al. A synthetic method for peptide-PEG-lipid conjugates: application of octreotide-PEG-DSPE synthesis. , 2008, Bioorganic & medicinal chemistry letters.
[8] H. Fang,et al. Evaluation of Multi-Target and Single-Target Liposomal Drugs for the Treatment of Gastric Cancer , 2008, Bioscience, biotechnology, and biochemistry.
[9] Hiroaki Arai,et al. Bootstrap re-sampling technique to evaluate the optimal formulation of theophylline tablets predicted by non-linear response surface method incorporating multivariate spline interpolation. , 2007, Chemical & pharmaceutical bulletin.
[10] U. Pagotto,et al. Octreotide, a somatostatin analogue, mediates its antiproliferative action in pituitary tumor cells by altering phosphatidylinositol 3-kinase signaling and inducing Zac1 expression. , 2006, Cancer research.
[11] Y. Hsiang,et al. Intracellular Target of the Anticancer Drug Camptothecin Identification of Mammalian DNA Topoisomerase I as an Updated , 2006 .
[12] C. Strock,et al. Activity of irinotecan and the tyrosine kinase inhibitor CEP-751 in medullary thyroid cancer. , 2006, The Journal of clinical endocrinology and metabolism.
[13] P. Courtoy,et al. Endocytosis of the somatostatin analogue, octreotide, by the proximal tubule-derived opossum kidney (OK) cell line. , 2005, Kidney international.
[14] Samuel Zalipsky,et al. Tumor cell targeting of liposome-entrapped drugs with phospholipid-anchored folic acid-PEG conjugates. , 2004, Advanced drug delivery reviews.
[15] H. Yanagie,et al. Liposomes Bearing Polyethyleneglycol-Coupled Transferrin with Intracellular Targeting Property to the Solid Tumors In Vivo , 2001, Pharmaceutical Research.
[16] Kensuke Matsumoto,et al. Antitumor activity of a camptothecin derivative, CPT-11, against human tumor xenografts in nude mice , 2004, Cancer Chemotherapy and Pharmacology.
[17] J. Taylor,et al. Somatostatin, but not somatostatin receptor subtypes 2 and 5 selective agonists, inhibits calcitonin secretion and gene expression in the human medullary thyroid carcinoma cell line, TT. , 2002, Hormone and metabolic research = Hormon- und Stoffwechselforschung = Hormones et metabolisme.
[18] A. Eberle,et al. Somatostatin analogs and radiopeptides in cancer therapy. , 2002, Biopolymers.
[19] A. Abbruzzese,et al. Current approaches and perspectives in the therapy of medullary thyroid carcinoma , 2001, Cancer.
[20] J. Taylor,et al. Somatostatin receptor subtypes 2 and 5 differentially affect proliferation in vitro of the human medullary thyroid carcinoma cell line tt. , 2001, The Journal of clinical endocrinology and metabolism.
[21] A. Beaudet,et al. Receptor‐mediated internalization of somatostatin in rat cortical and hippocampal neurons , 2000, Synapse.
[22] C. M. Huang,et al. Targeting delivery of paclitaxel into tumor cells via somatostatin receptor endocytosis. , 2000, Chemistry & biology.
[23] C. Beglinger,et al. Preclinical comparison in AR4-2J tumor-bearing mice of four radiolabeled 1,4,7,10-tetraazacyclododecane-1,4,7,10-tetraacetic acid-somatostatin analogs for tumor diagnosis and internal radiotherapy. , 2000, Endocrinology.
[24] H. Gharib,et al. Current diagnosis and management of medullary thyroid carcinoma. , 1998, Annals of oncology : official journal of the European Society for Medical Oncology.
[25] A. de Leiva,et al. Somatostatin and somatostatin receptor subtype gene expression in medullary thyroid carcinoma. , 1998, The Journal of clinical endocrinology and metabolism.
[26] P. Smith-Jones,et al. Synthesis and characterisation of [90Y]-Bz-DTPA-oct: a yttrium-90-labelled octreotide analogue for radiotherapy of somatostatin receptor-positive tumours. , 1998, Nuclear medicine and biology.
[27] G. Vitale,et al. Treatment of advanced medullary thyroid carcinoma with a combination of recombinant interferon α‐2b and octreotide , 1996, Cancer.
[28] A. Tabarin,et al. Results of long‐term continuous subcutaneous octreotide administration in 14 patients with medullary thyroid carcinoma , 1992, Clinical endocrinology.
[29] H. Kuga,et al. Intracellular roles of SN-38, a metabolite of the camptothecin derivative CPT-11, in the antitumor effect of CPT-11. , 1991, Cancer research.
[30] T. Visser,et al. In vivo use of a radioiodinated somatostatin analogue: dynamics, metabolism, and binding to somatostatin receptor-positive tumors in man. , 1991, Journal of nuclear medicine : official publication, Society of Nuclear Medicine.
[31] R. Ohno,et al. An early phase II study of CPT-11: a new derivative of camptothecin, for the treatment of leukemia and lymphoma. , 1990, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[32] M. Azria,et al. Disposition of sandostatin, a new synthetic somatostatin analogue, in rats. , 1989, Drug metabolism and disposition: the biological fate of chemicals.
[33] L. Liu,et al. Arrest of replication forks by drug-stabilized topoisomerase I-DNA cleavable complexes as a mechanism of cell killing by camptothecin. , 1989, Cancer research.
[34] L. Liu,et al. Topoisomerases: novel therapeutic targets in cancer chemotherapy. , 1988, Biochemical pharmacology.
[35] J. Rosenthaler,et al. Pharmacokinetics of SMS 201-995 in healthy subjects. , 1986, Scandinavian journal of gastroenterology. Supplement.
[36] L. Gráf,et al. Demonstration by immunofluorescence of the lipotropic hormone-LPH in bovine, ovine and procine adenohypophysis. , 1973, Hormone and metabolic research = Hormon- und Stoffwechselforschung = Hormones et metabolisme.